消水散联合利尿剂治疗癌性腹水的疗效及对患者免疫功能的影响

Clinical Effect of Xiaoshui Powder combined with Diuretic in Treatment of Cancerous Ascites and Influence on Immune Functions of Patients

目的:探讨自拟消水散联合利尿剂治疗癌性腹水的临床疗效。方法:选取恶性肿瘤伴癌性腹水患者84例,按随机数字表法分组,分别为42例,对照组予以常规利尿剂治疗,研究组予以自拟消水散联合利尿剂治疗。观察并比较两组患者治疗前后血清TNF-α,IL-2,IL-4,IL-6,CD3^+,CD4^+及CD4^+/CD8^+含量的变化情况以及临床疗效。结果:与治疗前对比,两组治疗后血清TNF-α,IL-2,IL-4及IL-6均降低,CD3^+,CD4^+及CD4^+/CD8^+均升高,CD8^+均降低,CEA,CA125,CA153及CA199均降低(P<0.05);与对照组对比,研究组治疗后血清TNF-α,IL-2,IL-4,IL-6较低,CD3^+,CD4^+及CD4^+/CD8^+较高,CD8^+较低,CEA,CA125,CA153及CA199较低(P<0.05);研究组治疗有效率高于对照组,差异具有统计学意义(P<0.05)。结论:消水散联合利尿剂治疗癌性腹水的疗效确切,能显著降低炎症指标及肿瘤标志物,提高机体免疫功能。

Objective： To investigate the clinical effect of Xiaoshui powder combined with diuretic in the treatment of cancerous ascites. Methods： 84 malignant tumor patients with cancerous ascites were selected and randomly divided into two groups, with 42 cases in each group. The patients in the control group were treated with routine diuretic therapy, while the patients in the experimental group were treated with Xiaoshui powder combined with diuretic therapy. Then the serum levels of TNF-α, IL-2, IL-4, IL-6, CD3^＋, CD4^＋ and CD4^＋/CD8^＋, and the clinical effect in the two groups were observed and compared before and after the treatment. Results： Compared with before treatment, the serum levels of TNF-α, IL-2, IL-4, IL-6, CD8＋, CEA, CA125, CA153 and CA199 in two groups decreased after treatment, while the serum levels of CD3^＋, CD4^＋ and CD4^＋/CD8^＋ increased （P〈0.05）; compared with the control group, the serum levels of TNF-α, IL-2, IL-4, IL-6, CD8^＋, CEA, CA125, CA 153 and CA199 were lower in the experimental group, while the serum levels of CD3＋, CD4^＋ and CD4^＋/CD8^＋ were higher （P〈0.05）. The clinical curative effect in the experimental group was higher than that of the control group, and the difference was statistically significant （P〈0.05）. Conclusion： Xiaoshui powder combined with diuretic in the treatment of cancerous ascites has better curative effect, which can significantly reduce the inflammatory factors and tumor markers, and improve the immune functions of patients.